Cowen & Co. Thinks Exelixis’ Stock is Going to Recover

Cowen & Co. analyst Boris Peaker maintained a Buy rating on Exelixis (NASDAQ: EXEL) today. The company’s shares closed yesterday at $17.35, close to its 52-week low of $15.81.

According to, Peaker is a 4-star analyst with an average return of 9.2% and a 42.7% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics Inc, Corvus Pharmaceuticals Inc, and Stemline Therapeutics Inc.

Currently, the analyst consensus on Exelixis is a Moderate Buy with an average price target of $28.60, which is a 64.8% upside from current levels. In a report released yesterday, Oppenheimer also initiated coverage with a Buy rating on the stock with a $40 price target.


See today’s analyst top recommended stocks >>

Based on Exelixis’ latest earnings release for the quarter ending June 30, the company reported a quarterly net profit of $87.49 million. In comparison, last year the company had a net profit of $81.16 million.

Based on the recent corporate insider activity of 56 insiders, corporate insider sentiment is negative on the stock. Most recently, in August 2018, Gisela Schwab, the Pres, Prod Dev & Med Aff & CMO of EXEL bought 50,000 shares for a total of $275,500.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of Cometriq, Cabometyx, and Cotellic.

From Our Partners